FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
|Articles|March 24, 2015
- Immunotherapy (Issue 5)
- Volume 5
- Issue 1
PD-1 Inhibitors for Melanoma
Author(s)Jason J. Luke, MD
Jason J. Luke, MD, assistant professor of medicine, The University of Chicago, discusses PD-1 inhibitors for the treatment of patients with melanoma.
Advertisement
Jason J. Luke, MD, assistant professor of medicine, The University of Chicago, discusses PD-1 inhibitors for the treatment of patients with melanoma.
Articles in this issue
over 11 years ago
The Rationale for Immunotherapy in NSCLCover 11 years ago
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancersover 11 years ago
Rich Immunotherapy Pipeline for Melanoma Under Wayover 11 years ago
Tumor Antigens and Their Role in Immune Response in Melanomaover 11 years ago
Major Programs Under Way in Immuno-Oncologyover 11 years ago
Immunotherapy in GU CancersAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5